B of A Securities Maintains Neutral on Perspective Therapeutics, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 54.2%

Neg 54.2% Neu 0% Pos 0%

B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.